Transforming cancer detection through precision diagnostics

How circulating tumour cell technology, AI and liquid biopsy are reshaping earlier, less invasive cancer diagnosis.

The biomedical sector is one of the fastest-growing areas of modern healthcare, driven by molecular biology, AI, genomics and precision medicine.

Less invasive treatment

Wider therapy options

Improved survival rates

Efficient resource use

A new window into cancer biology

CTC analysis identifies cancer cells in the bloodstream, giving clinicians insight into a cancer's presence, progression and biology through a blood-based test.

Get in touch

Where it applies

Breast
Prostate
Colorectal
Lung
Ovarian
Pancreatic

Screening has limits

Access, sensitivity and screening intervals all affect when cancer is caught.

AI accelerates analysis

AI can process imaging, pathology and genomic data at a speed clinicians alone cannot match.

Personalised medicine

Molecular biomarkers are moving care beyond a one-size-fits-all model.

Building on NHS progress

National screening and specialist care have improved survival, precision diagnostics and blood-based tests offer further opportunity to refine care.

A transformation in patient care

Companies developing clinically validated diagnostics are creating long-term value for providers, investors and patients alike.

Get in touch

Seed Enterprise Consulting Ltd is an introduction facilitator and does not provide financial advice, investment recommendations, or regulated financial services. We introduce HMRC-approved SEIS and EIS companies to private investors only. All investments carry risk. You could lose some or all of your capital. Tax reliefs depend on individual circumstances and are subject to change. Nothing on this website constitutes financial advice. Always seek independent advice before investing. Seed Enterprise Consulting Ltd is not authorised or regulated by the Financial Conduct Authority.